Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | CREBBP | Q92793 | 2/20 | 0.36 |
| ▸ | EP300 | Q09472 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
| ▸ | PLA2G2A | P14555 | 1/20 | 0.32 |
| ▸ | CA1 | P00915 | 3/20 | 0.32 |
| ▸ | CA2 | P00918 | 3/20 | 0.32 |
| ▸ | WDR5 | P61964 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 2/20 | 0.31 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3601976 | 0.88 | KMT2A (0.41) | KMT2AMEN1CREBBPEP300TSHR | |
| SCHEMBL3607261 | 0.83 | — | — | |
| SCHEMBL3601973 | 0.75 | KMT2A (0.46) | KMT2AMEN1CREBBPEP300PLA2G2A | |
| SCHEMBL3592397 | 0.74 | KMT2A (0.45) | KMT2AMEN1CREBBPEP300NPC1 | |
| SCHEMBL220900 | 0.70 | KMT2A (0.51) | KMT2AMEN1CREBBPEP300PLA2G2A | |
| SCHEMBL16396789 | 0.69 | RAB9A (0.48) | KMT2AMEN1TSHRNPC1RAB9A | |
| SCHEMBL16396946 | 0.69 | RAB9A (0.48) | KMT2AMEN1TSHRNPC1RAB9A | |
| SCHEMBL17802767 | 0.69 | RAB9A (0.48) | KMT2AMEN1TSHRNPC1RAB9A | |
| SCHEMBL3600893 | 0.68 | — | — | |
| SCHEMBL3588751 | 0.68 | GCK (0.41) | KMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7700640-B2 | Process for making phenoxy benzamide compounds | ASTRAZENECA AB (SE) | 2010-04-20 | — | — | US | disclosed |
| US-20080200694-A1 | Process for Making Phenoxy Benzamide Compounds | ASTRAZENECA AB (SE) | 2008-08-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080200694-A1 | Process for Making Phenoxy Benzamide Compounds | PAH, MAOB, TYR | KMT2A 726/4885MEN1 2346/4885CREBBP 390/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.